Back to Search
Start Over
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.
- Source :
-
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Feb 27. Date of Electronic Publication: 2024 Feb 27. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Details
- Language :
- English
- ISSN :
- 1476-5608
- Database :
- MEDLINE
- Journal :
- Prostate cancer and prostatic diseases
- Publication Type :
- Academic Journal
- Accession number :
- 38413763
- Full Text :
- https://doi.org/10.1038/s41391-024-00814-2